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Summary 
Insulin-dependent diabetes meUitus (IDDM) is thought o be an immunologically mediated is- 
ease resulting in the complete destruction of the insulin-producing islets of Langerhans. It has 
become increasingly clear that autoreactive T cells play a major role in the development and 
progression of this disease. In this study, we examined the role of the CD28/B7 costimulation 
pathway in the development and progression of autoimmune diabetes in the nonobese diabetic 
(NOD) mouse model. Female NOD mice treated at the onset of insulitis (2-4 wk of age) with 
CTLA4Ig immunoglobulin (Ig) (a soluble CD28 antagonist) or a monoclonal antibody (mAb) 
specific for B7-2 (a CD28 ligand) did not develop diabetes. However, neither of these treatments 
altered the disease process when administered late, at )10 wk of age. Histological examination 
of islets from the various treatment groups showed that while CTLA4Ig and anti-B7-2 mAb 
treatment blocked the development of diabetes, these reagents had little effect on the develop- 
ment or severity ofinsulitis. Together these results uggest that blockade ofcostimulatory signals 
by CTLA4Ig or anti-B7-2 acts early in disease development, after insulitis but before the onset 
of frank diabetes. NOD mice were also treated with mAbs to another CD28 ligand, B7-1. In 
contrast to the previous results, the anti-B7-1 treatment significantly accelerated the development 
of disease in female mice and, most interestingly, induced diabetes in normally resistant male 
mice. A combination of anti-B7-1 and anti-BT-2 mAbs also resulted in an accelerated onset of 
diabetes, similar to that observed with anti-BT-1 mAb treatment alone, suggesting that anti-BT-1 
mAb's effect was dominant. Furthermore, treatment with anti-B7-1 mAbs resulted in a more 
rapid and severe infiltrate. Finally, T cells isolated from the pancreases of these anti-B7-1-treated 
animals exhibited a more activated phenotype than T cells isolated from any of the other treat- 
ment groups. These studies demonstrate hat costimulatory signals play an important role in 
the autoimmune process, and that different members of the B7 family have distinct regulatory 
functions during the development of autoimmune diabetes. 
D iabetes is an autoimmune disease that results in the destruction of the insulin-producing islet cells (1). De- 
spite the development of new tools for the identification of 
individuals who are at risk for developing insulin-dependent 
diabetes mellitus (IDDM), I there are limited therapeutic op- 
tions to offer these future patients. Thus, current attempts 
1 Abbreviations u ed in this paper: Ctlg, control Ig; GAD, glutamic acid 
decarboxylase; H&E, hematoxylin a d eosin; IDDM, insulin-dependent 
diabetes meUitus; MFI, mean fluorescence intensity; NOD, nonobese di-
abetic. 
to develop useful immunosuppressive th rapies depends on 
a more complete understanding of the pathogenesis of disease. 
Illness in the nonobese diabetic (NOD) mice shares many 
common features with human IDDM, and this mouse strain 
has provided an important model for dissect!ng the patho- 
genesis of autoimmune diabetes (2, 3). NOD mice sponta- 
neously develop insulitis early in life (between 2 and 4 wk 
of age). However, it is not until 10-20 wk later that this 
insulitis progresses to diabetes in ~80%o of the female mice 
and in only 20% of the male mice. As in human IDDM, 
there is extensive vidence supporting a role for T cells and 
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MHC-restricted self-antigen recognition i the development 
of disease. First, T cells are among the earliest infiltrating 
cells in diseased islets (4, 5). Treatment of NOD mice with 
antibodies directed at T cell surface molecules such as CD4, 
CD8, and the TCR/CD3 complex prevent the development 
of disease and, in the case of anti-CD3 mAbs, blocked the 
progression of diabetes in a diabetic animal (6-8). Further- 
more, diabetes can be precipitated by adoptively transferring 
an islet-specific lone into young NOD mice (9, 10). 
One hypothesis for the development of autoimmune dis- 
ease is that the disruption of the normal mechanisms ofpe- 
ripheral tolerance may occur. For instance, recent studies have 
shown that the development of insulitis and diabetes in the 
NOD mouse correlates with the acquisition of T cell reac- 
tivity to glutamic acid decarboxylase (GAD) and a series of 
other islet antigens (11, 12). Indeed, NOD mice rendered 
tolerant o GAD by intravenous or intrathymic injection 
showed alower incidence of IDDM compared with control 
animals. Unfortunately, the therapeutic potential for tolerizing 
islet-specific T cells before their encounter with antigen is 
limited. Therefore, efforts have been devoted to altering the 
functional activity of autoreactive T cells after antigen rec- 
ognition in an attempt to promote atolerant rather than an 
activated state. Recent work has demonstrated that in addi- 
tion to TCR engagement byantigen, asecond signal, known 
as costimulation, is also required for T cell activation (13, 
14). Blockade of this costimulatory signal results in the in- 
duction of a state of antigen-specific nonresponsiveness known 
as anergy (13). Thus, one potential approach to inducing au- 
toreactive T cells into a tolerant state might be to block these 
costimulatory events. Studies performed in transgenic mice 
support his possibility. The ecotopic expression of MHC 
class I or II molecules on nonprofessional APCs, such as the 
islets of Langerhans, is not enough to activate potentially au- 
toreactive T cells (15, 16). However, the coexpression f the 
appropriate costimulatory molecules, such as B7-1, on the 
islets activates these cells and results in the autoimmune de- 
struction of the islets (17-19). Therefore, the potential to regu- 
late T cell costimulation provides apotent new approach to 
altering the functional activity of autoreactive T cells. 
While the costimulatory signals involved in IDDM are 
currently unknown, there are many cell surface molecules 
that may deliver the necessary costimulatory signal. Evidence 
suggests that the major T cell costimulatory pathway involves 
the CD28-B7 family of costimulatory molecules. CD28 is 
expressed on the majority of naive and memory T cells (20, 
21). Activation of T cells with anti-CD28 mAb blocks the 
induction of anergy and synergizes with anti-CD3 stimula- 
tion to increase both T cell proliferation and lymphokine 
production in vitro (22-25). Furthermore, F(ab) fragments 
of anti-CD28 inhibit the activation of T cells and, in some 
instances, renders them anergic (22). 
There are two known natural ligands for CD28. B7-1 was 
the first ligand to be identified and is expressed on "pro- 
fessional" APC, such as dendritic ells, macrophages, and 
activated B cells (26-30). In vitro studies using B7-1 trans- 
fectants demonstrated that B7-1 costimulated both antigen- 
and mitogen-driven T cell proliferation and IL-2 production 
by interacting with CD28 (31, 32). Recently, we and others 
have identified a second CD28 ligand, B7-2, which is also 
expressed on "professional" APC (33-36). Cloning of the 
B7-2 molecules has revealed sequence similarity to B7-1, and 
it has been shown to bind to the CD28 molecule (37-39). 
Antibodies to B7-2 are more effective than anti-B7-1 mAb 
at blocking T cell responses to natural APC, such as in an 
allogeneic mixed lymphocyte r action (40, 41). Furthermore, 
prolongation of allogeneic slet graft survival occurred under 
the cover of anti-B7-2 but not anti-B7-1 mAb treatment, sug- 
gesting that the B7-2 costimulatory molecule plays a more 
dominant role than B7-1 in this immune response (Zeng, J., 
Lenschow, D. J., and Bluestone, J. A., manuscript submitted 
for publication). 
CTLA-4 is a cell surface molecule, with sequence homology 
to CD28, expressed on activated CD4 + and CD8 + T cells 
(42, 43). Although CTLA-4 may not function as a costimula- 
tory molecule, a soluble fusion protein comprising the ex- 
tracellular domain of CTLA-4 and the Fc portion of human 
IgG1 constant region, CTLA4Ig, binds both B7-1 and B7-2 
and has been used to inhibit a variety of CD28-dependent 
immune responses, including in vivo antibody responses and 
allogeneic and xenogeneic graft rejection (44-46). In fact, 
in a xenogeneic islet transplant model, blockade of the 
CD28/B7 costimulatory pathway with CTLA4Ig led to the 
induction of donor-specific tolerance (46). 
In this study, we examined the role of the CD28/B7 sig- 
naling pathway in the initiation and propagation of autoim- 
mune diabetes in the NOD mouse. While blockade of this 
costimulatory pathway with either CTLA4Ig or antioB7-2 
mAb prevented isease development, treatment with anti- 
B7-1 or a combination of anti-B7-1 and anti-B7-2 mAbs 
resulted in a more rapid onset of disease in both female and 
male mice. These results indicate that the CD28/B7 costimula- 
tory pathway is involved in the control of this autoimmune 
response and may provide apowerful target o alter the func- 
tion of autoreactive T cells and human disease progression. 
Materials and Methods 
Mice. NOD mice were purchased from The Jackson Labora- 
tory (Bar Harbor, ME) and Taconic Farms, Inc. (Germantown, NY) 
and were bred in a specific pathogen-free animal facility at the 
University of Chicago. C57BL/6 (B6) mice were purchased from 
The Jackson Laboratory and were maintained in a pathogen-free 
animal facility at the University of Chicago. 
Antibodies. In initial studies, human CTLA4Ig and a control 
fusion protein, L6Ig, were provided by Bristol-Myers Squibb Phar- 
maceutical Research Institute (Seattle, WA) (47). Later studies were 
performed with CTLA4Ig provided by R~ligen Corp. (Cambridge, 
MA) (33) and a control human Ig purchased from Sigma Chemical 
Co. (St. Louis, MO). Similar esults were obtained with both sets 
of reagents. The hamster anti-routine B7-1 mAb (16-10A1) was 
provided by Repligen Corp. The rat anti-routine B7-1 mAb (1G10) 
was generated aspreviously described (48). The rat anti-routine 
B7-2 mAb (GL1) was produced inan Acusyst Jr. bioreactor (Coons 
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River, MN) and was purified by passage over a protein G-coupled 
Sepharose column (35). HTC-coupled anti-Thyl and anti-B220 
mAbs and biotin-coupled anti-CD4, anti-CDS, and anti-CD69 were 
purchased from PharMingen (San Diego, CA). PE-coupled strep- 
tavidin was purchased from Southern Biotechnology Associates (Bir- 
mingham, AL). 
Treatment Protocol. Groups of NOD mice were treated with 
CTLA4Ig, anti-B7-1 mAbs (16-10A1 and 1G10), anti-B7-2 mAb 
(GL1), and control Abs (L6Ig and Ctlg) as follows. Male and fe- 
male NOD mice between 2 and 3 wk of age were treated with 
50 #g of either control Jibs (L6Ig or Ctlg), CTLA4Ig, anti-B7-1 
mAb (1G10 or 16-10A1), or anti-B7-2 mAb (GL1) every other day 
for 14 d. Animals then received one additional 50-#g dose at weeks 
6, 7, and 8. Animals receiving both anti-B7-1 (16-10A1) and anti- 
B7-2 mAb treatment received 50 #g of each mAb. To test he effects 
of these reagents on later stages of the disease, female NOD mice 
were treated with 50 #g of the above reagents hree times per week 
starting at 80 d of age for '~10 wk, or until the animals became 
diabetic. Animals treated with control antibodies beginning at 2 
wk of age showed aslight delay in the development of diabetes 
(12 wk) compared with untreated mice (10 wk) although the 
penetrance of disease was the same by 24 wk of age, with nearly 
90% of both control treated and untreated female mice becoming 
diabetic by 24 wk of age. 
Assessment of Diabetes. Starting at 7 wk of age, diabetes was 
assessed by weekly measurements of blood glucose levels by use 
of a glucose meter (One Touch II; Lifescan, Inc., Milpitas, CA). 
Glucose strips were kindly provided by Lifescan, Inc. Animals were 
considered iabetic after two consecutive measurements >250 
mg/dl. Onset of diabetes was dated from the first of the sequential 
diabetic measurements. 
Histological Analysis. The pancreases from killed animals were 
fixed in buffered formalin and embedded in paraffin. 4-/zm sections 
were cut and hematoxylin a d eosin (H&E) staining was performed. 
To determine the severity of insulitis in the various treatment groups, 
four to six animals per time point (4, 8, and 12 wk) were analyzed, 
and multiple tissue sections of the pancreases foreach animal were 
scored for insulitis. At least 50 islets were counted per time point. 
Islets were scored blindly and found to be either free of insulitis 
(score = 0), exhibiting periinsulitis (lymphocytes surrounding the 
islets and ducts but not infiltrating the islet architecture; score = 
1), exhibiting moderate insulitis (lymphocytes infiltrating <50% 
of the islet architecture; score = 2), or exhibiting severe insulitis 
(>50% of the islet tissue infiltrated by lymphocytes; score = 3). 
Mean clinical score = severity score x number islets in that cate- 
gory/number of mice. 
Pancreatic Lymphocyte Isolation. Pancreases from animals within 
the same treatment group were minced into 2-4-ram fragments. 
These fragments were then digested in an enzyme mixture con- 
taining 5 mg of hyaluronidase (Sigma Chemical Co.), 1,500 U of 
DNase (Sigma Chemical Co.), and 50 mg of collagenase P 
(Boehringer Mannheim Biochemicals, Indianapolis, IN) in 50 ml 
of complete media (DMEM, 10% FCS, 2 mM L-glutamine, 25#M 
Hepes buffer, 100 U penicillin, 100 #g/ml streptomycin, 2 mM 
nonessential amino acids, and 5 x 10-5 M 2-ME). This mixture 
was incubated atroom temperature for60 min with constant stir- 
ring, then I ml of FCS was added, and the mixture was incubated 
for an additional 60 rain. A single-cell suspension was obtained 
by filtering through anytex screen. The cells were washed twice, 
resuspended in 10 ml media, and then fractionated on a discon- 
tinuous BSA density gradient by layering 10 ml of 35% BSA (Sigma 
Chemical Co.) under 10 ml of 24% BSA, which had been layered 
under the 10 ml of complete media containing the ceUs. After cen- 
trifugation at 1,400 rpm for 40 min, the interface between the 35 
and 24% layers was removed, washed twice, and then analyzed 
by FACS | (Becton Dickinson & Co., Mountain View, CA) for 
subsets and activation markers. 
Flow Cytometric Analysis. 10 s spleen cells or pancreatic lym- 
phocytes were washed in FACS | buffer (0.1% BSA and 0.01% so- 
dium azide in I x PBS) and then incubated with FITC or biotin- 
coupled staining reagents for 30 min at 4~ The cells were then 
washed in FACS | buffer. Biotin-coupled reagents were developed 
with PE-coupled streptavidin bystaining for 15 min at 4~ The 
cells were then washed in FACS | buffer, and two-color flow cytom- 
etry was performed by use of a FACScan | flow cytometer (Becton 
Dickinson & Co.). Data were analyzed with the Lysis II software 
program (Becton Dickinson & Co.). Data were collected on 104 
cells based on forward-scatter intensity and exclusion of dead cells 
based on staining with propidium iodide. 
Results 
Early Treatment ofNOD Mice with CTLA4Ig Prevents the 
Development of Diabetes. The development ofautoimmune 
disease in the NOD mouse begins at between 2 and 4 wk 
of age as evident by the infiltration of the islet of Langerhans 
by lymphocytes (5, 49). This insulitis is an essential step in 
the development of full-blown diabetes 8-20 wk later. We 
therefore treated NOD mice beginning at "~2-3 wk of age, 
presumably atthe onset of insulitis. Animals received either 
CTLA4Ig or control antibody (Ctlg) at a dose of 50 #g every 
other day for 2 wk followed by three additional 50-#g injec- 
tions at weeks 6, 7, and 8. Female mice were continually 
monitored for the development of diabetes. While "~87% 
of the animals treated with Ctlg developed isease between 
weeks 12 and 33, treatment with hCTLA4Ig blocked the 
development of diabetes (Fig. 1). Only 11% of the treated 
female mice became diabetic by 33 wk of age in contrast to 
the 87% of the Ctlg-treated animals. Within 24 h after the 
last injection, we could no longer detect serum levels of 
CTLA4Ig due to the animals mounting a vigorous antibody 
response to the human protein (data not shown). These results 
indicate that a relatively short treatment protocol that inter- 
mpts the CD28/B7 costimulatory pathway either by directly 
signaling or blocking important interactions between members 
of the CD28/B7 family during a critical time in disease de- 
velopment prevents IDDM in female NOD mice. 
CTLA4Ig's Interaction with B7-2 Plays an Important Role in 
Preventing Disease. CTLA4Ig's ability to inhibit the devel- 
opment of diabetes could have resulted from the binding of 
CTLA4Ig to either of its two natural ligands, B7-2 or B7-1. 
We have previously shown that while both molecules have 
the ability to costimulate T cell responses, under physiologic 
conditions, B7-2 appears to play the dominant costimulatory 
role both in vitro and in vivo (33, 40). Anti-BT-2 mAb, but 
not anti-B7-1 mAbs, inhibits an allogeneic mixed lympho- 
cyte response and prolongs aUogeneic islet graft survival (Zeng, 
J., et al., manuscript submitted for publication). We there- 
fore examined irectly the role of B7-2 in the development 
of autoimmune diabetes in the NOD mouse model. 
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Figure 1. Early treatment of" NOD mice with CTLA4Ig and anti-B7-2 
mAbs prevents the development ofdiabetes. Female NOD mice were treated 
with CTLA4Ig ([3; n = 19), anti-B7-2 mAb (A; n = 11), and Ctlg 
(O; n = 16) as described in Materials and Methods. Beginning at 8 wk 
of age, diabetes was assessed by weekly measurements of blood glucose levels. 
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Figure 2. The late treatment of NOD mice has no effect on disease 
progression. NOD mice were treated with either Ctlg (O; n = 13) or 
CTLA41g (I-1; n = 29) three times a week for at least 8 wk, or until 
the development of diabetes, beginning at ,,o10 wk of age (80 d). The 
development of diabetes was monitored as described. 
CTLA41g 9 
2-wk-old NOD mice were treated with the anti-B7-2 mAb 
(GL1) as described above and followed for the development 
of diabetes. Only 45 % of the anti-BT-2-treated mice became 
hyperglycemic by 33 wk of age, in contrast o 87% of con- 
trol treated mice (Fig. 1). Of the five anti-B7-2-treated animals 
that did develop diabetes, four of them did not develop dis- 
ease until at least 18 wk of age. Therefore, anti-B7-2 treat- 
ment was able to delay disease onset and block disease devel- 
opment in a subset of mice. However, its ability to induce 
and maintain tolerance to IDDM may not be as efficient as 
CTLA4Ig, in which only 11% of the treated animals became 
diabetic. 
Late Treatment ofNOD Mice with CTLA4Ig Has No Effect 
on Disease Outcome. While the first evidence of disease can 
be detected as early as 3-4 wk of age with the occurrence 
ofinsulitis, full-blown diabetes does not develop until much 
later. These observations have suggested that at least two 
different events must occur to precipitate the eventual devel- 
opment of diabetes. To examine what effect the CTLA4Ig 
treatment had when initiated well after the induction of in- 
sulitis, but before any clinical signs of disease, such as hyper- 
glycemia, had developed, we started treatment of NOD mice 
when they were 80 d old. Animals were treated three times 
a week for 10 wk, or until the onset of disease, and moni- 
tored for the development ofdiabetes. Despite the ability of 
CTLA4Ig to inhibit disease development when administered 
early, it had little effect on disease outcome when treatment 
was initiated late in the disease process (Fig. 2). Therefore, 
it appears that the inhibitory effects of these reagents are ex- 
erted during early phases of the disease process, either before 
the initiation of disease or just subsequent to the initial an- 
tigen engagement by islet-reactive cells. 
Effects of CD28 Antagonists onthe Occurrence oflnsulitis. To 
begin to address the mechanism by which CTLA4Ig and anti- 
B7-2 prevent disease, we examined treated animals for one 
of the earliest signs of diabetes, the development of insulitis. 
Pancreatic tissue from 8-wk-old female mice treated with Ctlg, 
CTLA4Ig, or anti-B7-2 mAbs were prepared and examined 
for insulitis. Insulitis could be detected in all of the treat- 
ment groups, including the CTLA4Ig and anti-B7-2-treated 
mice (data not shown). To further examine the development 
ofinsulitis in these animals, male and female mice were killed 
at 4, 8, and 12 wk of age, and histological sections of their 
pancreases were prepared and scored for the presence ofinsu- 
litis. Despite the ability of CTLA4Ig and anti-B7-2 mAbs 
to inhibit the development of disease, the presence of insu- 
litis was readily detectable atall times. By 4 wk of age, '-30% 
of the islets from Ctlg (mean clinical score --- 7.45), CTLA4Ig 
(mean clinical score -- 4.13), and anti-B7-2 mAb- (mean clin- 
ical score -- 7.25) treated female mice showed evidence of 
cell infiltration although the majority of the insulitis was non- 
destructive periinsulitis (Fig. 3). The severity of the infiltrate 
continued to increase at 8 wk of age in all groups, although 
both the CTLA4Ig-and anti-B7-2 mAb-treated groups ap- 
peared to have a slightly more severe infiltrate at this time 
than did the Ctlg-treated animals. By 12 wk of age, all three 
groups had between 40 and 60% of their islets infiltrated 
by lymphocytes, and the severity had increased (Ctlg mean 
clinical score = 16.28; CTLA4Ig mean clinical score = 24.0; 
anti-B7-2 mAb mean clinical score = 16.75). Similar results 
were also observed in the treated males (data not shown). 
Thus, the inhibition of disease development induced by 
CTLA4Ig and anti-B7-2 treatment was not caused by a quan- 
titative difference in the T cell infiltrate into the islets, and 
therefore these treatments must alter a later event in this disease. 
Treatment of NOD Mice with a Combination of Anti-B7-1 
and Anti-B7-2 mAbs Accelerates Disease Onset. Previous results 
in an aUogeneic transplant model demonstrated that acom- 
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Figure 3. The incidence of insulitis in NOD 
mice treated with CD28 antagonists. Female 
animals from the various treatment groups were 
killed at 4, 8, and 12 wk of age. Pancreatic sec- 
tions were stained with H&E and then scored 
for the presence of periinsulitis ( olid hars)i mod- 
erate insulitis (cross-hatched bars), oi: severe insu- 
litis (shaded Mrs). Three to six animals (at least 
50 islets) from each time point were scored, ln- 
sulitis is reported as the percentage ofinfiltrated 
islets per total islets scored for each treatment 
group and time point. 
bination of anti-B7-1 and anti-B7-2 mAbs was more im- 
munosuppressive than either drug alone (Zeng, J., et al., manu- 
script submitted for publication). Therefore, we examined 
the ability of the combined therapy to block the develop- 
ment of diabetes inNOD mice. 2-3-wk-old mice were treated 
with both anti-B7-2 and anti-B7-1 (16-10A1) mAbs as de- 
scribed in Materials and Methods. Despite the ability of anti- 
B7-2 mAb to inhibit disease onset, treatment with a combi- 
nation of anti-B7-1 and anti-B7-2 mAbs resulted in an ac- 
celerated onset on disease (Fig. 4). By 12 wk of age, >65% 
of the combined treated female mice developed diabetes, and 
by 16 wk of age, all but one animal were hyperglycemic. Treat- 
ment of 2-wk-old NOD mice with the anti-B7-1 mAb (16- 
10A1) alone also made the disease worse (Fig. 4). In fact, 
hyperglycemia was detected in some mice as early as 8 wk 
of age in both treatment groups. More than 80% of the anti- 
B7-1-treated female mice were diabetic by week 12, and by 
16 wk of age, 100% of the female mice were hyperglycemic. 
In contrast, at 16 wk of age only 20% of the Ctlg-treated 
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Figure 4. A combination of anti-B7-1 (16-10A1) and anti-BT-2 mAbs 
accelerates the onset of diabetes. Female NOD mice were treated at 2 wk 
of age with control Ig (O; n = 16), anti-B7-1 (O; n = 17), or both 
anti-B7-1 and anti-B7-2 ro_Abs (A; n = 18) as described. The treated animals 
were then monitored for the development of diabetes. 
animals were diabetic, with only 70% developing diabetes 
by 24 wk of age. To eliminate the possibility that this phe- 
nomenon was due to nonspecific toxicity of the 16-10A1 mAb, 
these studies were repeated with another anti-B7-1 mAb, 1G10. 
As shown in Fig. 5 A, treatment of the female NOD mice 
with 1G10 also accelerated the development ofdiabetes. 100% 
of the 1G10-treated female mice became diabetic by week 18. 
Even more striking than the exacerbation of disease in the 
female mice was the observation that anti-B7-1 treatment in- 
duced disease in normally resistent male NOD mice (Fig. 
5 B). Disease was first detected in these anti-B7-1- (16- 
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Figure 5. Anti-B7-1 therapy accelerates disease in both male and fe- 
male NOD mice. Female (A) and male (B) NOD mice were treated with 
control Ig (O; female n = 16, male n = 10) or one of two anti-B7-1 
mAbs: 16-10A1 (O; female n = 17, male n = 15) or 1G10 ( , ;  female 
n = 5, male n = 9) beginning at 2 wk of age as described and followed 
for the development of diabetes. 
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10A1)-treated male mice at 8 wk of age. By 24 wk of age, 
73% of these male mice had developed iabetes, while there 
was autoimmune diabetes in only 20% of the control-treated 
mice. Furthermore, 1G10 treatment resulted in the develop- 
ment of diabetes in >50% of the male NOD mice (Fig. 5 
B). Finally, as seen with CTLA4Ig, treatment of NOD mice 
after 10 wk of age with anti-B7-1 mAbs did not alter the 
development of diabetes (data not shown). 
Treatment of NOD Mice with Anti-B7-1 mAbs Alters Early 
Events in Disease Development. The development ofinsulitis 
was also examined in these anti-B7-1-treated animals. While 
all of the treatment groups exhibited insulitis at 8 wk of age 
in the anti-B7-1-treated mice, the islets appeared to be more 
severely infiltrated, with few if any intact islets remaining 
(data not shown). Further analysis of these mice revealed that 
anti-B7-1 treatment increased the time course and severity 
of insulitis in both male and female mice. As seen in Fig. 
3, while anti-B7-1-treated female mice did not exhibit an 
overall increase in the percentage of islets affected at 4 wk 
of age, the severity of the infiltrate was increased (Ctlg [mean 
dinical score .= 7.45] and anti-B7-1 mAb [mean clinical score 
= 10.35]). By 8 wk of age, the effect was even more dra- 
matic, with >70% of the islets from anti-B7-1-treated mice 
demonstrating moderate to severe insulitis. In fact, >50% 
of the islets had a severe insulitis, resulting in a complete loss 
of the islet architecture, compared with 10-26% in the other 
treatment groups (Fig, 3). While at 12 wk of age the per- 
centage of islets infiltrated in the other groups was nearing 
that of the anti-B7-1-treated group, the severity of the infiltrate 
in the anti-B7-1 mAb-treated mice (mean dinical score = 
41.33) was much greater than either the Ctlg (mean dinical 
score = 16.28) or the CTLA4Ig (mean clinical score = 24.0) 
treated mice. A similar increase in the severity of insulitis 
was also observed in the anti-B7-1-treated male mice (data 
not shown). 
We also examined the effects of anti-B7-1 mAb treatment 
in normal B6 mice. 2-wk-old animals were treated as previ- 
ously described with anti-B7-1 mAb (16-10A1). Anti-B7-1- 
treated male and female B6 mice were monitored for 30 wk 
for the development of diabetes or insulitis. None of the treated 
animals developed any signs of diabetes, including insulitis. 
12-wk-old B6 mice treated with either Ctlg (a) or anti-B7-1 
(16-10A1) mAb (b) demonstrated no signs of lymphocytic 
infiltrates into either the islets or pancreas (Fig. 6). In con- 
trast, the islets of a 12-wk-old NOD mouse treated with anti- 
B7-1 (d) displayed severe infiltrate into all of the islets present 
within the pancreas. Ctlg-treated NOD mice (c) also exhibited 
signs of lymphocytic infiltrate, although once again, not as 
severe as in the anti-B7-1-treated animals. Therefore, the anti- 
B7-1 mAb did not induce disease in the absence of the genetic 
predisposition. 
Finally, we examined the cellular makeup of the pancreatic 
infiltrate in the various treatment groups. Pancreases from 
treated animals were isolated at 11-13 wk of age, and the 
infiltrating lymphocytes were examined. Both T and B cells 
were present in all of the groups, with 12-20% of the infiltrate 
being composed of B220 + ceils and 30--42% of it composed 
of Thyl § cells (data not shown). The CD4/CD8 ratios 
were also similar between all of the groups. Analysis of T 
cell activation by CD69 expression (50-52) demonstrated that 
T cells isolated from the pancreases of all of the female treat- 
ment groups were activated to some degree (mean fluores- 
cent intensity [MFI] of control-treated animals = 10.85) com- 
pared with either splenic T cells from the same animals (MFI 
of control animals = 3.39) or age-matched male mice (MFI 
of control animals -- 4.79). However, CD69 expression of 
pancreatic T cells isolated from both the male and female 
anti-B7-1-treated mice was significantly increased above the 
levels observed in the Ctlg-, CTLA4Ig-, or anti-B7-2-treated 
animals (Fig. 7). The female anti-B7-1-treated mice exhibited 
a mean fluorescence intensity of nearly 2.5 times that of Ctlg- 
treated female mice, and the male mice expressed levels 1.75 
times that of Ctlg-treated male mice. While Fig. 7 suggests 
that treatment with anti-B7-2 mAb resulted in a reduced ex- 
pression of CD69 in the T cells isolated from the spleen or 
male pancreases, this was not observed in repeated experi- 
ments. The increased expression of CD69 on the B7-1-treated 
pancreatic T cells together with the increased severity of in- 
sulitis indicate that anti-B7-1 treatment alters a very early 
event in the disease process, resulting in an accelerated onset 
of disease. 
Discussion 
One model for the induction of T cell tolerance suggests 
that the inability of nonconventional APC to fully activate 
T cells due to their lack of costimulatory molecules results 
in T cell inactivation (anergy) and, in some instances, cell 
death. While several studies have demonstrated that the ec- 
topic expression of MHC molecules and the appropriate 
costimulatory molecules on nonconventional cells, such as 
the islets of Langerhans, can induce an autoimmune destruc- 
tion of the islets (17-19), few studies have directly examined 
the role of costimulatory signals during the normal develop- 
ment of autoimmune diabetes. In this study, we examined 
the role of the CD28/B7 signaling pathway in the genera- 
tion and propagation of autoimmune diabetes in the NOD 
mouse model. 
CTLA4Ig, a soluble CD28/B7 antagonist, has been shown 
to inhibit a variety of responses, including allogeneic and 
xenogeneic transplant rejection (45, 46), antibody responses 
(44), and autoimmune disease (53). In this study, CTLA4Ig 
treatment of NOD mice also resulted in a profound inhibi- 
tion of disease onset when administered just before or at the 
onset of insulitis. Only 11% of the CTLA4Ig-treated mice 
became diabetic. Similar results were observed with an anti- 
B7-2 mAb, GL1, previously shown to be the dominant 
costimulatory CD28 ligand in aUogeneic responses (33). Anti- 
B7-2 mAb treatment of NOD mice inhibited iabetes when 
initiated at 2 wk of age, with only 45% of the anti-B7- 
2-treated mice becoming diabetic compared with 87% of 
control treated mice. In both instances, the CD28 antago- 
nists had no effect on the development of disease if administered 
late (>10 wk of age). These results uggest that these inhibi- 
tory reagents block early events in disease development. The 
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Figure 6. Anti-B7-1 treatment only induces insulitis in genetically susceptible strains of mice. NOD and B6 mice were treated with either anti-B7-1 
(16-10A1) or a Ctlg beginning at 2 wk of age as described in Materials and Methods. Representative H&E sections of 12-wk-old mice are shown. 
(a) Ctlg-treated B6, (b) anti-B7-1-treated B6, (c) Ctlg-treated NOD, and (d) anti-B7-1-treated NOD. x200. 
inability of CTLA4Ig to block the development ofdiabetes 
when administered late in the disease process differs rom the 
observations of Finck et al. (53) that late treatment could 
suppress an active autoimmune r sponse in a model for mu- 
rine lupus. This difference may be due to the more predomi- 
nant role of antibodies in the lupus model or a difference 
in reagents, since in these studies only murine and not human 
CTLA4Ig had a beneficial effect. 
While both CTLA4Ig and anti-B7-2 mAb treatment were 
able to decrease the incidence of diabetes, they had little effect 
Figure 7. Phenotypic analysis of]ymphocytes infiltrating the pancreas 
of treated animals. T cells isolated from either the spleen or pancreas of 
11-13-wk-old treated mice were analyzed for surface expression of CD69 
by FACS | analysis. The percentage ofcontrol mean fluorescence = (MFI 
of treatment group/MFI of control group) x 100. TheMFI for the control- 
treated animals are female splenic T cells = 3.39, female pancreatic T cells 
= 10.85, and male pancreatic T cells = 4.79. Each group is composed 
of five mice, and the data are representative of two experiments. 
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on the occurrence ofinsulitis. CTLA4Ig- and anti-B7-2-treated 
animals developed an equivalent lymphocytic nfiltrate to that 
of Ctlg-treated animals, so that by 12 wk of age, the mean 
clinical scores were essentially equivalent. Similar results were 
also obtained in treated male mice, although asignificant de- 
gree of infiltration (>40% of the islets) was not detected until 
12 wk of age (data not shown). Isolation of the lymphocytes 
infiltrating the pancreas demonstrated that equivalent umbers 
of T cells (CD4 and CDS) and B cells were present in all 
three groups. Moreover, the degree of T cell activation, as 
assessed by the expression of CD69, was equivalent in the 
Ctlg-, CTLA4Ig-, and anti-B7-2-treated groups. Therefore, 
quantitatively, the infiltrate appears to be quite similar be- 
tween Ctlg-treated animals that develop disease and CTLA4Ig- 
or anti-B7-2-treated animals that do not. However, qualita- 
tive differences in the infiltrate may exist. One possibility is 
that the interruption of critical interactions between CD28 
and its costimulatory ligands may result in the induction of 
anergy to islet antigens uch as GAD65. These antigens have 
been shown to play an important role in the early phase of 
the development of disease (11, 12). Alternatively, CTLA4Ig 
and anti-B7-2 treatment may inhibit disease, not by inducing 
anergy to these islet antigens, but by altering the balance of 
Thl and Th2 cells that infiltrate the islets and respond to 
the autoantigens (54). In fact, recent data from Kuchroo et 
al. (54a) have suggested that the in vivo functional effects 
of anti-B7-2 mAbs in an experimental utoimmune n- 
cephalomyelitis (EAE) model are a result of changes in the 
balance of Thl and Th2 subsets in these animals. 
While anti-B7-2 treatment inhibited iabetes development 
in NOD mice, its effects were not as profound as CTLA4Ig 
treatment. This could be due to the differences in affinity 
of the mAb and CTLA4Ig for B7-2 or CTLA4Ig's ability 
to bind to alternative ligands, such as B7-1. Therefore, NOD 
mice were treated with either a combination ofanti-B7-1 plus 
anti-B7-2 mAbs or anti-B7-1 alone. In contrast o the im- 
munosuppression f NOD disease observed after anti-B7-2 
or CTLA4Ig therapy, treatment of NOD mice with anti- 
B7-1 mAbs at the onset of insulitis resulted in a more severe 
infiltrate and a rapid onset of disease in both male and female 
mice. This effect was observed with two different anti-B7-1 
mAbs, 16-10A1 and 1G10, even though 1G10 has a 40-fold 
lower avidity for B7-1 than does 16-10A1 (33). Unlike the 
CTLA4Ig or anti-B7-2 treatment, which had little effect on 
the development of insulitis, the treatment of NOD mice 
with anti-B7-1 mAbs resulted in a more severe and rapid onset 
of insulitis. Furthermore, the T ceils isolated from the anti- 
B7-1-treated female and male mice expressed higher levels 
of CD69, indicating they were more highly activated than 
T ceils isolated from the other treatment groups. 
These results indicate that B7-1 plays a direct role in con- 
trolling this autoimmune response by directly signaling 
through the B7-1 molecule, interrupting a critical interac- 
tion between B7-1 and one of its ligands, or interacting with 
a distinct population of APC during the development ofdis- 
ease. Interestingly, transfectants of both B7-1 and B7-2 are 
capable of providing the necessary costimulatory signals to 
the T cell (37-39). However, differences in both the expres- 
sion and function of these two molecules have been observed. 
The expression orB7-2 occurs much more rapidly than B7-1 
after B cell activation (33, 41). Furthermore, Ig cross-linking 
only induces ignificant levels of B7-2 and not B7-1 (40). Thus, 
it is possible that B7-2 is expressed on APC essential for ini- 
tiating full-blown diabetes, while B7-1 is expressed on cells 
that regulate the development of insulitis. For instance, B7-1 
is expressed on activated T cells (55). Thus, the anti-B7-1 
mAb might deliver a signal to the T cells that alters effector 
cell function, such as lymphokine production, resulting in 
a potential shift in the balance of Thl and Th2 subsets. Al- 
ternatively, the interaction of the anti-B7-1 mAb with con- 
ventional APC could increase the antigen presentation or
costimulation capabilities of the cells, resulting in a more po- 
tent T cell response. Finally, anti-B7-1 treatment may mediate 
its effects by blocking the interaction of B7-1 with one of 
its counter-receptors, CTLA-4 (43). Recent data from our 
laboratory suggest that the signals delivered to the T cell by 
CD28 and CTLA-4 may be different. F(ab) fragments of anti- 
CTLA-4 antibodies augment T cell proliferation in an 
allogeneic MLK by blocking an off signal presumably deliv- 
ered by a CTLA-4 ligand (42). These results uggest the pos- 
sibility that while the CD28 molecule provides important 
costimulatory signals to the T cell, CTLA-4/B7-1 interac- 
tions may actually function to dowrtregnlate an immune 
response. The interruption of such a negative signal by anti- 
B7-1 mAbs would prevent the downregulation f an autoim- 
mune response and result in a more severe disease. 
Despite the ability of anti-B7-2 mAb to inhibit costimula- 
tion and prevent diabetes, a combination of anti-B7-1 and 
anti-B7-2 mAbs increased the onset of diabetes in both fe- 
male and male mice (data not shown), similar to anti-B7-1 
mAb treatment alone. These results raise the possibility that 
B7-1 and B7-2 function at different ime points during the 
development and propagation of this autoimmune r sponse. 
In this regard, there is good evidence that this disease progresses 
in at least wo stages (56). The first event results in the devel- 
opment of insulitis, and later events are responsible for the 
progression to full-blown diabetes. While both CTLA4Ig 
and anti-B7-2 treatment inhibited the development of dia- 
betes, neither treatment prevented the occurrence of insu- 
litis. Furthermore, animals not receiving the additional three 
doses at weeks 6, 7, and 8 were not protected from developing 
diabetes (data not shown). Together, these results suggest 
that anti-B7-2 and CTLA4Ig treatment act late in disease 
development. In contrast, anti-B7-1 mAbs increased both the 
rate and severity of insulitis, and the additional three doses 
at weeks 6, 7, and 8 were not necessary for exacerbation f
disease (data not shown), suggesting that this therapy altered 
the initial stages of the disease process. There are several pos- 
sible explanations for the exacerbation fdisease observed with 
a combination of anti-B7-1 and anti-B7-2 mAbs. First, it is 
possible that the initial activation event may be CD28 inde- 
pendent. If this is the case, then this event would rely on 
alternative costimulatory pathways and would therefore not 
be affected by blockade of the CD28 ligands, B7-1 or B7-2. 
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In this regard, it is interesting to note that early alloantigen 
responses are largely unaltered in vivo or in vitro in CD28- 
deficient mice (57). By comparison, the later events of dis- 
ease progression would appear to be exclusively CD28 
dependent. Alternatively, all of the stages of autoimmune di- 
abetes may be CD28 dependent, and the initiation of treat- 
ment at 2 wk of age is not early enough to prevent the de- 
velopment of insulitis, but would inhibit the later events 
responsible for disease progression. In either case, autoreac- 
tive T cells would be activated and express both CTLA-4 
and B7-1. Therefore, the exacerbation f disease mediated by 
the anti-B7-1 mAb would dominate the inhibitory effects of 
anti-B7-2 treatment by either directly signaling through the 
B7-1 molecule or interrupting a critical interaction respon- 
sible for shutting down the immune response. Future experi- 
ments with Fab and F(ab)~ fragments of the anti-B7-1 and 
anti-B7-2 mAbs, as well as genetically altered B7-1 and B7-2 
knockout mice, will allow us to determine the mechanism 
by which B7-1 treatment exacerbates disease. 
Finally, these observations do not appear to be restricted 
to the NOD autoimmune mouse model. Preliminary studies 
performed in collaboration with Dr. Steve Miller (North- 
western University, Chicago, IL) in an EAE model have shown 
that treatment of mice with anti-B7-1 during the primary 
response to proteolipid protein resulted in more rapid and 
severe secondary relapses (Miller, S., C. Vanderlugt, D.J. Len- 
schow, and J. A. Bluestone, unpublished observations). There- 
fore, the mechanism responsible for the anti-B7-1-mediated 
acceleration of disease in the NOD mouse model may be 
similar for other autoimmune diseases. 
In conclusion, these results dearly demonstrate that T cell 
costimulation is an essential component of the in vivo acti- 
vation of autoreactive T cells and the development of autoim- 
mune diabetes. Thus, the manipulation ofthis costimulation 
pathway may provide a powerful new target for the develop- 
ment of future therapies for diabetes and other autoimmune 
diseases. 
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